Gene analysis in individuals tumors associated with likelihood of pathologic complete remission with neoadjuvant chemotherapy in breast cancer.
At least 3% of all cancer cases are attributed to hereditary variation in cancer predisposition genes, and 5-20% of breast cancer or ovarian cancer cases are linked to genetic abnormalities.
ER expression makes the strongest impact on the gene expression patterns of breast cancers.
In hereditary breast cancers may distinguish BRCA1 from BRCA2 based on gene expression profiles.
Gene profiling is commonly used to determine breast cancer recurrence.
Gene expression profiling had been validated with the recurrence score (RS) for breast cancer.